Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

This study analyzed patient-reported outcomes (PROs) from NRG/RTOG 1010, a randomized trial adding trastuzumab to standa...

Continue ReadingPatient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

Providing holistic care for patients with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions.

This review article discusses metabolic dysfunction-associated steatotic liver disease (MASLD) as a highly prevalent con...

Continue ReadingProviding holistic care for patients with metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis: Key aspects of clinical assessment and how to develop individualised care plans for surveillance and interventions.

Incorporating artificial intelligence into imaging for surveillance and diagnosis of liver cancer: Innovations, challenges, and clinical translation.

This publication is a narrative review on the role of artificial intelligence (AI) in the management of primary liver ca...

Continue ReadingIncorporating artificial intelligence into imaging for surveillance and diagnosis of liver cancer: Innovations, challenges, and clinical translation.